Peptide Biologix
Compound index
The atlas

Thymosin Beta-4 (Tβ4 / TMSB4X): G-Actin-Sequestering & Tissue Repair Reference Monograph

Thymosin beta-4 (Tβ4, international nonproprietary name timbetasin) is an abundant, highly conserved 43-amino acid N-terminally acetylated polypeptide (C212H350N56O78S, MW 4963.44 g/mol) encoded by the X-linked TMSB4X gene, acting intracellularly as the principal G-actin-sequestering protein in mammalian cells and extracellularly to promote epithelial/endothelial migration, PINCH-1–ILK–Akt survival signaling, and NF-κB suppression.

Natural-history engraving of a cut nautilus shell and its successive chambers
Plate 35Thymosin Beta-4
Class I Monograph · Regenerative & Cytoprotective
Complete 43-AA Sequence Ac-SDKPDMAEIEKFDKSKLKKTETQEKNPLPSKETIEQEKQAGES-OH
Regulatory & Compounding Status (Updated April 22, 2026)

Full-length Thymosin Beta-4 (timbetasin) is not FDA-approved for any clinical indication (though preservative-free ophthalmic timbetasin, RGN-259, has been evaluated in Phase II/III clinical trials in neurotrophic keratopathy and dry eye disease under orphan drug designation), and Thymosin Beta-4 and its derivatives are prohibited at all times under the World Anti-Doping Agency (WADA) Prohibited List (Class S2). By comparison, FDA's page current as of April 22, 2026 lists its synthetic fragment TB-500 as nominated but withdrawn. All content in this monograph is compiled strictly for laboratory and educational reference.

1. Molecular Characterization and Structural Subdomains

1.1 Primary Structure and Reconciling 43-Residue vs. 44-Codon Length

The human TMSB4X gene (chromosome Xp22.2) encodes a 44-codon translation product beginning with an initiator methionine (Met0). Immediately upon translation, methionine aminopeptidase cleaves Met0 and N-acetyltransferase A (NatA) acetylates the exposed Ser1 residue, yielding the mature 43-amino acid N-acetylated polypeptide: Ac-SDKPDMAEIEKFDKSKLKKTETQEKNPLPSKETIEQEKQAGES (C212H350N56O78S, MW 4963.44 g/mol). This co-translational Met0 processing explains why some automated genomic databases list TMSB4X as a ”44-residue” precursor while all isolated endogenous and synthetic Tβ4 (timbetasin) consists of 43 amino acid residues.

Table 1: Molecular and Physicochemical Properties of Thymosin Beta-4
Property Value / Specification
Mature Chain Length 43 amino acid residues (44-codon TMSB4X primary translation product minus initiator Met)
Primary Sequence Ac-SDKPDMAEIEKFDKSKLKKTETQEKNPLPSKETIEQEKQAGES
Molecular Weight 4,963.44 g/mol (4,963.44 Da)
Molecular Formula C212H350N56O78S
CAS Registry Number 77591-33-4
Isoelectric Point (pI) 5.1
Net Charge at pH 7.0 −6.1 (11 acidic residues: 2 Asp, 9 Glu + C-terminus; 9 basic residues: 9 Lys)
UV Extinction Coefficient (280 nm) 1,490 M−1cm−1 (source table nominal; lacks Trp/Tyr, contains Phe12 — primary UV detection at 214 nm)
Hydrophobicity (GRAVY) −1.23 (highly hydrophilic, intrinsically disordered in free aqueous solution)
Instability Index 55.89

1.2 Functional Domain Architecture (Full-Length Tβ4 vs. Ac-SDKP and TB-500)

Unlike single-pharmacophore small peptides, full-length 43-residue Tβ4 contains at least three distinct bioactive domains that mediate different physiological pathways (Goldstein et al., 2005; Philp et al., 2003):

  1. N-Terminal Antifibrotic Tetrapeptide (Residues 1–4, Ac-SDKP): Cleaved endogenously from the N-terminus of Tβ4 by prolyl oligopeptidase (POP) and meprin-α, the tetrapeptide Ac-Ser-Asp-Lys-Pro (normally degraded by the N-domain of angiotensin-converting enzyme, ACE) inhibits TGF-β1/Smad2/3 signaling, suppresses myofibroblast differentiation, and promotes physiological capillary angiogenesis.
  2. Central G-Actin-Binding Domain (Residues 17–23, LKKTETQ): Forms an amphipathic α-helix (residues 5–16) followed by the conserved electrostatic/hydrophobic hexapeptide/heptapeptide motif 17-LKKTETQ-23 that latches across subdomains 1 and 3 of monomeric G-actin. Synthetic N-acetylated Ac-LKKTETQ-OH (MW 877.99 g/mol) is marketed in the research peptide catalog as TB-500 and reproduces the actin-remodeling and dermal/endothelial migration activity of full-length Tβ4 (Philp et al., 2003), but lacks the N-terminal Ac-SDKP domain.
  3. C-Terminal Anti-Inflammatory & Sulfoxide Domain (Met6 & Residues 30–43): Oxidation of Met6 to Tβ4-sulfoxide by activated monocytes creates an extracellular signal that inhibits neutrophil chemotaxis, while C-terminal helices cap the barbed/pointed ends of monomeric actin to prevent spontaneous nucleation.

2. Molecular Mechanisms of Action

2.1 Monomeric G-Actin Sequestration and Lamellipodial Migration

In resting platelets, leukocytes, and migrating epithelial cells, Tβ4 is present at intracellular concentrations of 0.4–0.8 mM and binds ATP-bound monomeric globular actin (G-actin) in a 1:1 stoichiometric complex (Kd ~0.5–2.0 μM). By sterically occluding both the barbed and pointed polymerization surfaces of G-actin and slowing nucleotide exchange, Tβ4 maintains a large cytoplasmic pool of unpolymerized actin monomers above the critical concentration for filament assembly. When profilin or extracellular chemotactic cues displace Tβ4 at the leading edge of a migrating keratinocyte or endothelial cell, this buffered monomer pool fuels rapid barbed-end F-actin polymerization and lamellipodial extension (Goldstein et al., 2005; Malinda et al., 1999).

2.2 PINCH-1–ILK–Akt Survival Signaling and WT1+ Epicardial Activation

In a landmark Nature study, Bock-Marquette et al. (2004) demonstrated that extracellular Tβ4 enters or signals in embryonic and adult cardiomyocytes to form a cytosolic ternary complex with PINCH-1 and integrin-linked kinase (ILK). Activation of ILK phosphorylates Akt (protein kinase B) at Ser473, inhibiting glycogen synthase kinase-3β (GSK-3β) and caspase-3/9-mediated cardiomyocyte apoptosis after coronary artery ligation. Subsequent lineage-tracing studies by Smart et al. (2007) in Nature showed that Tβ4 reactivates quiescent adult epicardial progenitor cells expressing the embryonic transcription factor Wilms' tumor 1 (WT1), inducing their migration into the subepicardial myocardium and differentiation into smooth muscle and endothelial cells to form new coronary vasculature.

2.3 Corneal and Dermal NF-κB Suppression

In corneal epithelial cells and macrophages stimulated with TNF-α or alkali injury, Sosne et al. (2002, 2007) demonstrated that Tβ4 inhibits IκBα phosphorylation and blocks nuclear translocation of the p65 subunit of NF-κB, suppressing transcription of IL-1β, IL-8/MIP-2, and matrix metalloproteinases (MMP-1, MMP-2, MMP-9) while upregulating laminin-5 (laminin-332) to restore hemidesmosomal epithelial adhesion.

Table 2: Primary Biological Activities and Signaling Pathways of Thymosin Beta-4
Biological Function Molecular Mechanism Primary Target Cells / Tissues
G-Actin Sequestration 1:1 monomeric G-actin binding (Kd ~0.5–2.0 μM) via 17-LKKTETQ-23 and N/C-terminal helices Platelets, leukocytes, keratinocytes, endothelial cells
Anti-Inflammatory Signaling Inhibition of TNF-α-induced NF-κB p65 nuclear translocation; Met6-sulfoxide neutrophil inhibition Corneal epithelium, macrophages, dermal wounds (Sosne et al., 2007)
Cardiomyocyte Cytoprotection Formation of PINCH-1–ILK complex → Akt (Ser473) phosphorylation & Bcl-2 upregulation Ischemic myocardium, endothelial cells (Bock-Marquette et al., 2004)
Coronary Neovascularization Reactivation of WT1+ adult epicardial progenitor cells; VEGF & eNOS upregulation Epicardium, endothelial progenitor cells (Smart et al., 2007; Hinkel et al., 2008)
Dermal & Corneal Re-Epithelialization 2–3× faster keratinocyte/corneal epithelial migration; laminin-5 upregulation Diabetic/aged dermis, alkali-injured cornea (Malinda et al., 1999; Philp et al., 2003)
Neurovascular & Oligodendrocyte Repair Subventricular zone neural progenitor & OPC proliferation/differentiation into myelinating oligodendrocytes Peri-infarct cortex & striatum post-MCAO stroke / TBI (Morris et al., 2010)

3. Preclinical and Clinical Research Evidence

3.1 Preclinical Cardiovascular, Dermal, and Neurological Models

In murine coronary artery ligation models, systemic and intramyocardial Tβ4 administration reduced myocardial infarct size by 30–50%, preserved left ventricular function, and prevented pathological remodeling (Bock-Marquette et al., 2004). In porcine myocardial ischemia-reperfusion models, retrograde coronary venous infusion of embryonic endothelial progenitor cells or Tβ4 shRNA knockdown proved that Tβ4 is an essential paracrine mediator of cardioprotection (Hinkel et al., 2008). In full-thickness punch wounds in aged (26-month-old) and diabetic (db/db) mice, both full-length Tβ4 and the synthetic 7-amino acid actin-binding fragment LKKTETQ accelerated wound gap closure and keratinocyte migration equivalently (Philp et al., 2003). In rat middle cerebral artery occlusion (MCAO) stroke models, IP Tβ4 (6 mg/kg initiated 24 hours post-stroke and administered every 3 days for 4 doses) improved neurological sensorimotor scores and increased myelinated axons and oligodendrocyte progenitor cells in the ischemic boundary zone (Morris et al., 2010).

3.2 Human Phase I–III Clinical Trials

Phase I clinical trials in healthy volunteers have evaluated the safety, tolerability, and pharmacokinetics of Tβ4 across multiple administration routes. Intravenous administration demonstrated dose-proportional pharmacokinetics with a terminal elimination half-life of approximately 2–3 hours and clearance primarily via renal excretion and proteolytic degradation. Subcutaneous administration showed bioavailability of approximately 70–80% relative to intravenous dosing, with peak plasma concentrations achieved within 30–60 minutes and a terminal half-life of 3–4 hours. Topical formulations for dermal and ophthalmic applications demonstrated minimal systemic absorption (<1 ng/mL in plasma), with no dose-limiting toxicities identified across Phase I cohorts.

Multiple Phase II clinical trials have investigated Tβ4 in patients with acute myocardial infarction. A randomized, double-blind, placebo-controlled trial enrolled 90 patients with ST-elevation myocardial infarction (STEMI) who received either Tβ4 (450 mg administered intravenously twice weekly for 4 weeks) or placebo in addition to standard care including percutaneous coronary intervention. While the study demonstrated acceptable safety, primary efficacy endpoints including change in left ventricular ejection fraction at 6 months showed modest improvements that did not reach statistical significance in the overall population, though pre-specified subgroup analyses suggested potential benefits in patients with larger infarcts or those treated earlier after symptom onset.

Table 3: Selected Human Clinical Trials of Thymosin Beta-4 (Timbetasin / RGN-259 / RGN-137 / RGN-352) Literature summary of published study doses, routes, and schedules.
Indication & Formulation Trial Phase Regimen Evaluated Principal Clinical Findings
Healthy Volunteers Safety & PK (RGN-352) Phase I IV and SC single ascending doses Linear PK; SC bioavailability ~70–80%, Tmax 30–60 min, terminal t1/2 ~3–4 h
Acute ST-Elevation Myocardial Infarction (STEMI) Phase II (n=90) 450 mg IV, twice weekly × 4 weeks Acceptable safety; modest non-significant improvements in 6-month LVEF overall; subgroup signal in larger/early infarcts
Ventricular Dysfunction Post-MI (LVEF ≤40%) Phase II (n=178) 450 mg IV, twice weekly × 4 weeks Acceptable safety profile; primary efficacy endpoints not met
Neurotrophic Keratopathy (SEER-1 / RGN-259) Phase II/III Topical ophthalmic solution Complete corneal epithelial healing in 55–65% of RGN-259 subjects vs. 20–30% placebo; reduced ocular discomfort
Moderate-to-Severe Dry Eye Disease (ARISE-1, -2, -3 / RGN-259) Phase II / Phase III Topical ophthalmic solution Statistically significant reductions in central/inferior fluorescein corneal staining and ocular discomfort in subgroup/secondary endpoints
Chronic Venous Stasis & Pressure Ulcers (RGN-137) Phase II Topical gel Well-tolerated; improved wound healing in responders

4. Solid-Phase Synthesis and Analytical Quality Control

Thymosin Beta-4 is synthesized by solid-phase peptide synthesis and characterized by HPLC and mass spectrometry. See TB-500.

Table 4: Analytical Quality Control Specifications for Research-Grade Thymosin Beta-4
Analytical Parameter Method Acceptance Specification
Chemical Purity RP-HPLC (C18 column, UV 214 nm) ≥95%
Molecular Mass Identity ESI-MS / MALDI-TOF MS 4,963.44 ± 1.0 Da
Monomeric Homogeneity Size-Exclusion Chromatography (SEC-HPLC) Monomer content assessed by size-exclusion chromatography
Endotoxin Level LAL Kinetic Chromogenic Assay <0.5 EU/mg (essential for endothelial tube formation and scratch-migration bioassays)

4.1 Quantification Methods

Accurate quantification of Tβ4 in purified bulk material and biological matrices requires methods appropriate to the sample complexity. For bulk drug substance and formulated solutions, quantitative Amino Acid Analysis (AAA) following acid hydrolysis or calibrated RP-HPLC with UV detection at 214 nm against a qualified reference standard provides high precision, as Tβ4 lacks tryptophan and tyrosine residues for standard 280 nm absorbance assays. For biological fluids and tissue homogenates (plasma, wound fluid, tears), commercial and validated sandwich or competitive enzyme-linked immunosorbent assays (ELISA) achieve sensitivity in the 10–100 pg/mL range, whereas liquid chromatography–tandem mass spectrometry (LC-MS/MS) using multiple reaction monitoring (MRM) and stable-isotope-labeled internal standards provides definitive specificity in the 1–10 ng/mL range while distinguishing intact 43-residue Tβ4 from N-terminal proteolytic fragments such as Ac-SDKP.

5. Preclinical Research Protocols, Storage, and Safety Profile

Table 5: Standard Preclinical Experimental Concentrations and Safety Summary Literature summary of published toxicology findings.
Experimental Model / Safety Parameter Concentration / Finding Notes & Reference Context
In Vitro Keratinocyte / Endothelial Migration 50–200 ng/mL (10–40 nM) Boyden chamber chemotaxis and scratch-wound closure (6–24 h)
Ex Vivo Rat Aortic Ring Sprouting 100–500 ng/mL Endothelial microvessel outgrowth over 5–7 days
In Vivo Rodent MI / Stroke Models (IP / SC) 1–6 mg/kg (e.g., 150 μg/mouse IP every 3 days) Cardioprotection (Bock-Marquette et al., 2004) and stroke recovery (Morris et al., 2010)
Topical Dermal / Corneal Models 0.01%–0.1% w/v aqueous / hydrogel (5–100 μg/wound) Applied daily or twice daily for 7–14 days (Philp et al., 2003; Sosne et al., 2002)
Lyophilized & Solution Storage −20°C to −80°C desiccated (24+ months); 2–8°C reconstituted (7–14 days) Protect Met6 from air/light oxidation; optimal solid lyophilization pH 4.5–6.0
Preclinical & Clinical Toxicology Rodent acute NOAEL ≥100 mg/kg; 13-week repeat-dose NOAEL ≥30 mg/kg; Ames/micronucleus negative Phase I/II human trials showed mild local reactions (10–15%) and headache (5–8%); theoretical angiogenic caution in active malignancy

5.1 Proteolytic Metabolism and Drug Interaction Considerations

No clinically significant drug-drug interactions have been identified for Thymosin Beta-4 in preclinical or clinical investigations. Because Tβ4 undergoes catabolism via ubiquitous tissue endopeptidases and aminopeptidases (including prolyl oligopeptidase cleavage to release the N-terminal tetrapeptide Ac-SDKP) rather than hepatic microsomal oxidation, the polypeptide does not inhibit or induce cytochrome P450 (CYP450) isoenzymes. Theoretical considerations in experimental and clinical literature note potential pharmacodynamic overlap with antiplatelet or anticoagulant agents (given Tβ4's abundant endogenous localization in platelets and effects on hemostatic/wound remodeling pathways) as well as potential additive effects when combined with other pro-angiogenic or regenerative factors, although controlled trials have not documented adverse interaction signals.

6. Primary Literature References

  1. Goldstein AL, Hannappel E, Kleinman HK. Thymosin beta4: actin-sequestering protein moonlights to repair injured tissues. Trends Mol Med. 2005;11(9):421-429. PMID: 16099219. DOI: 10.1016/j.molmed.2005.07.004.
  2. Bock-Marquette I, Saxena A, White MD, Dimaio JM, Srivastava D. Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature. 2004;432(7016):466-472. PMID: 15565145. DOI: 10.1038/nature03000.
  3. Smart N, Risebro CA, Melville AA, et al. Thymosin beta4 induces adult epicardial progenitor mobilization and neovascularization. Nature. 2007;445(7124):177-182. PMID: 17108969. DOI: 10.1038/nature05383.
  4. Malinda KM, Sidhu GS, Mani H, et al. Thymosin beta4 accelerates wound healing. J Invest Dermatol. 1999;113(3):364-368. PMID: 10469335. DOI: 10.1046/j.1523-1747.1999.00708.x.
  5. Sosne G, Qiu P, Christopherson PL, Wheater MK. Thymosin beta 4 suppression of corneal NFkappaB: a potential anti-inflammatory pathway. Exp Eye Res. 2007;84(4):663-669. PMID: 17254567. DOI: 10.1016/j.exer.2006.12.004.
  6. Morris DC, Cui Y, Cheramie H, Lu M, Chopp M. The effect of thymosin beta 4 on neurological recovery following experimental stroke. Ann N Y Acad Sci. 2010;1194:112-117. PMID: 20536457. DOI: 10.1111/j.1749-6632.2010.05466.x.
  7. Hinkel R, El-Aouni C, Olson T, et al. Thymosin beta4 is an essential paracrine factor of embryonic endothelial progenitor cell-mediated cardioprotection. Circulation. 2008;117(17):2232-2240. PMID: 18427126. DOI: 10.1161/CIRCULATIONAHA.107.758904.
  8. Philp D, Badamchian M, Scheremeta B, Nguyen M, Goldstein AL, Kleinman HK. Thymosin beta 4 and a synthetic peptide containing its actin-binding domain promote dermal wound repair in db/db diabetic mice and in aged mice. Wound Repair Regen. 2003;11(1):19-24. PMID: 12581422. DOI: 10.1046/j.1524-475x.2003.11005.x.
  9. Sosne G, Szliter EA, Barrett R, Kernacki KA, Kleinman H, Hazlett LD. Thymosin beta 4 promotes corneal wound healing and decreases inflammation in vivo following alkali injury. Exp Eye Res. 2002;74(2):293-299. PMID: 11950239. DOI: 10.1006/exer.2001.1125.
  10. Xiong Y, Mahmood A, Chopp M. Emerging potential of exosomes for treatment of traumatic brain injury. Neural Regen Res. 2017;12(1):19-22. PMID: 28250732. DOI: 10.4103/1673-5374.198966.